Ivabradine

Ivabradine
Clinical data
Pronunciation	/ɪˈvæbrədiːn/
Trade names	Corlanor, Procoralan, others
Other names	S-16257
AHFS/Drugs.com	Monograph
MedlinePlus	a615027
License data	US DailyMed: Ivabradine;
Routes of; administration	By mouth
ATC code	C01EB17 (WHO) C07FX05 (WHO), C07FX06 (WHO);
Legal status
Legal status	CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	40%
Protein binding	70%
Metabolism	Liver (first-pass) >50%, CYP3A4-mediated
Elimination half-life	6 hours
Excretion	Kidney and fecal
Identifiers
	IUPAC name 3-[3-({[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one;
CAS Number	155974-00-8 ;
PubChem CID	132999;
IUPHAR/BPS	2357;
DrugBank	DB09083 ;
ChemSpider	117373 ;
UNII	3H48L0LPZQ;
KEGG	D07165 ;
ChEBI	CHEBI:85966 ;
ChEMBL	ChEMBL471737 ;
CompTox Dashboard (EPA)	DTXSID2048240 ;
Chemical and physical data
Formula	C27H36N2O5
Molar mass	468.594 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2N(CCc1cc(OC)c(OC)cc1C2)CCCN(C[C@@H]4c3cc(OC)c(OC)cc3C4)C;
	InChI InChI=1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3/t21-/m1/s1 ; Key:ACRHBAYQBXXRTO-OAQYLSRUSA-N ;
	(what is this?) (verify)

Ivabradine, sold under the brand name Procoralan among others, is a medication, which is a pacemaker current (I_f) inhibitor, used for the symptomatic management of heart-related chest pain and heart failure. Patients who qualify for use of ivabradine for congestive heart failure are patients who have symptomatic heart failure, with reduced ejection fraction, and heart rate at least 70 bpm, and the condition not able to be fully managed by beta blockers.^[3]

Ivabradine acts by inducing negative chronotropy in the sinoatrial structure, thus reducing the heart rate via specific inhibition of the pacemaker current. It operates by a mechanism different from that of beta blockers and calcium channel blockers, which are two commonly prescribed antianginal classes of cardiac drugs. Ivabradine has no apparent inotropic properties and may be a cardiotonic agent.

^ "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
^ "Procoralan EPAR". European Medicines Agency (EMA). 25 October 2005. Retrieved 7 September 2024.
^ Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. (September 2016). "2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America". Circulation. 134 (13): e282 – e293. doi:10.1161/CIR.0000000000000435. PMID 27208050.{{cite journal}}: CS1 maint: overridden setting (link)

[1] "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.

[2] "Procoralan EPAR". European Medicines Agency (EMA). 25 October 2005. Retrieved 7 September 2024.

[Van2016-3] Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. (September 2016). "2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America". Circulation. 134 (13): e282 – e293. doi:10.1161/CIR.0000000000000435. PMID 27208050.{{cite journal}}: CS1 maint: overridden setting (link)

[1]

[2]

[3]